Showing results (2711-2720 of 3,166) with videos related to
Sort By:
Pageof 317
Neuro-Oncology|December 9, 2008
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphomaSofiane Maza, Philipp Kiewe, Dieter L Munz, et al.Neuro-Oncology|December 11, 2008
Secretory meningiomas: a benign subgroup causing life-threatening complicationsJan Regelsberger, Christian Hagel, Pedram Emami, et al.Neuro-Oncology|December 11, 2008
Incidence of and survival from oligodendroglioma in Denmark, 1943-2002Malene Schjønning Nielsen, Helle Collatz Christensen, Michael Kosteljanetz, et al.Neuro-Oncology|November 26, 2008
Identifying Muir-Torre syndrome in a patient with glioblastoma multiformeDeric M Park, Gabrielle A Yeaney, Ronald L Hamilton, et al.Neuro-Oncology|November 13, 2008
Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specificPeter Jun, Chibo Hong, Anita Lal, et al.Neuro-Oncology|February 21, 2009
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastomaAndrea Pirzkall, Colleen McGue, Suja Saraswathy, et al.Neuro-Oncology|April 1, 2009
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumabEudocia C Quant, Andrew D Norden, Jan Drappatz, et al.Neuro-Oncology|April 1, 2009
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosisKevin R Kozak, John S MoodyNeuro-Oncology|October 30, 2008
AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrixYuji Piao, Li Lu, John de GrootNeuro-Oncology|February 13, 2009
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastomaNichole L Bryant, Catalina Suarez-Cuervo, G Yancey Gillespie, et al.Pageof 317